Guardant Health shares fell after the FDA announced a review of AstraZeneca’s camizestrant application for advanced breast cancer. The news is a modest negative for Guardant because any delay or uncertainty around a related breast cancer therapy can weigh on sector sentiment and associated diagnostics names. No financial figures were disclosed.
Guardant Health shares fell after the FDA announced a review of AstraZeneca’s camizestrant application for advanced breast cancer. The news is a modest negative for Guardant because any delay or uncertainty around a related breast cancer therapy can weigh on sector sentiment and associated diagnostics names. No financial figures were disclosed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.22
Ticker Sentiment
